logo

Last Update

This profile was last updated on 8/14/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Dante Pieramici?

Dante J. Pieramici

Co-Director

California Retina Consultants

HQ Phone:  (805) 963-1648

Email: d***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

California Retina Consultants

515 E Micheltorena St

Santa Barbara, California,93103

United States

Company Description

California Retina Consultants is a group of vitreoretinal specialists that provide comprehensive medical and surgical treatments for all disorders of the retina, macula and vitreous. They focus on the diagnosis, prevention and treatment of these conditions. Ma...more

Web References(60 Total References)


Dante J. Pieramici, MD - SEE International

www.seeintl.org [cached]

Dante J. Pieramici, MD
Dante J. Pieramici, MD Dr. Dante J. Pieramici regularly trains international ophthalmologists from underserved areas around the world. An esteemed ophthalmologist himself, he is also the Co-Director of the California Retina Research Foundation, a partner of the California Retina Consultants, Assistant Clinical Professor of Ophthalmology at the Doheny Eye Center in Southern California, and serves on the Board of Directors at SEE International. Dr. Pieramici has published over 100 articles, 16 book chapters, and has edited 3 books on retinal diseases. He lectures nationally and internationally on retinal diseases and ocular trauma. His research interests vary, and include clinical and basic science projects aimed at better understanding of the underlying pathophysiology of ocular diseases. Through these efforts, Dr. Pieramici hopes to improve treatments for patients with age-related macular degeneration, diabetic retinopathy, retinal vascular diseases, and severe ocular injuries. In addition to his research, Dr. Pieramici has helped in the development of new surgical techniques, including limited macular translocation and 25-gauge (small incision) vitrectomy surgery. He is also involved in the development of new drug delivery techniques for various retinal vascular diseases. Dr. Pieramici has received the Achievement Award from the American Academy of Ophthalmology and Honor Award from the American Society of Retinal Specialists. He is a member of the American Academy of Ophthalmology, the Retina Society, the Macula Society, the American Society of Retinal Specialists, the Association for Research in Vision and Ophthalmology, the American Society of Ocular Trauma where he serves as Vice President, and the Pan-American Ophthalmologic Society, among others. Dr. Pieramici graduated with honors from the Johns Hopkins University School of Medicine and completed his Ophthalmology Residency at the Wilmer Eye Institute. He has held full-time academic positions at the Yale University Eye Center and the Wilmer Eye Institute, where he served as the Assistant Chief of Service and Director of Ocular Trauma.


Leadership - SEE International

www.seeintl.org [cached]

Dante J. Pieramici, MD
Dante J. Pieramici, MD Dr. Dante J. Pieramici regularly trains international ophthalmologists from underserved areas around the world. An esteemed ophthalmologist himself, he is also the Co-Director of the California Retina Research Foundation, a partner of the California Retina Consultants, Assistant Clinical Professor of Ophthalmology at the Doheny Eye Center in Southern California, and serves on the Board of Directors at SEE International.


Advanced Studies in Ophthalmology

www.jhasio.com [cached]

Dante J. Pieramici, MD
Co-Director, The California Retina Research Foundation Assistant Clinical Professor, Doheny Eye Institute Partner, California Retina Consultants


SEE International :: Board of Directors

webmail.seeintl.org [cached]

Dante J. Pieramici, MD
Dante J. Pieramici, MD is a Santa Barbara-based ophthalmologist who works out of California Retina Consultants. Dr. Pieramici holds a number of appointments: Vice President of the American Society of Ocular Trauma, Director of the California Eye Trauma Registry, Co-Director of the California Retina Research Foundation, and Visiting Assistant Professor of the Wilmer Ophthalmological Institute at the Johns Hopkins Hospital. Past appointments include Secretary/Treasurer of the United States Eye Injury Registry, Assistant Professor for the Department of Ophthalmology at Yale University, and Director of the Wilmer Ocular Trauma Service. Dr. Pieramici received his Bachelor's degree in Neurobiology from Northwestern University and his medical degree from Johns Hopkins University. He has written over 100 publications concerning eye disease.


Retinal Physician -

www.retinalphysician.com [cached]

Dante J. Pieramici, MD, a partner in California Retina Consultants and director of the California Retina Research Foundation in Santa Barbara, California, estimates 30% to 50% of his patients who have DME that involves or is threatening the center of the vision, have the disease in both eyes.
Generally, if treatment is needed, he treats both eyes during one visit, but there are exceptions and considerations. Dr. Pieramici doesn't typically adjust the drug dosage when treating both eyes. "However, in a high-risk patient, such as someone who has had a recent myocardial infarction or a stroke, I'm more apt to select a drug that has demonstrated lower systemic absorption, such as ranibizumab (Lucentis, Genentech) or perhaps a steroid," he says. Follow-up Period Dr. Pieramici notes the differences between treating AMD and DME are important to remember, particularly when both eyes are involved. "From the DRCR.net Protocol I and other trials where PRN dosing was used,3-7 we've seen that we can at least reduce the treatment burden in DME," he says. "Having a completely or near completely dry macula, which is often our goal with AMD, doesn't appear to be necessary when treating DME," Dr. Pieramici says. "We don't see these types of challenges as often among patients with AMD, most of whom have more complete insurance coverage under Medicare," Dr. Pieramici says. "The DME patients may have insurance with high deductibles and copayments that must be paid at every visit, or they may not have insurance at all, meaning they have to pay out-of-pocket for their treatments." Some pharmaceutical companies offer assistance programs for patients. "These programs can help offset the cost of anti-VEGF drug copayments, and can help patients who have no means to pay for the drugs," Dr. Pieramici says. Encourage Control "Patients with diabetic eye disease, particularly bilateral disease, need to be encouraged to control their systemic health," Dr. Pieramici says.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory